ValiRx plc (LSE:VAL) — Market Cap & Net Worth
Market Cap & Net Worth: ValiRx plc (VAL)
ValiRx plc (LSE:VAL) has a market capitalization of $3.05 Million (£2.27 Million) as of September 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #29526 globally and #591 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ValiRx plc's stock price £0.15 by its total outstanding shares 742721072 (742.72 Million). Also see ValiRx plc (VAL) total assets for a full breakdown of the balance sheet.
ValiRx plc Market Cap History: 2015 to 2026
ValiRx plc's market capitalization history from 2015 to 2026. Data shows change from $2.84 Trillion to $144.62 Million (-60.05% CAGR). Also see ValiRx plc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
ValiRx plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$902.54 Million | 0.34% | #66 of 722 |
Weight: ValiRx plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ValiRx plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ValiRx plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check VAL stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
15529.69x
ValiRx plc's market cap is 15529.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.84 Trillion | $82.60K | -$2.12 Million | 34337438.25x | N/A |
| 2023 | $5.88 Billion | $9.60K | -$2.04 Million | 612989.56x | N/A |
| 2024 | $772.99 Million | $49.77K | -$1.92 Million | 15529.69x | N/A |
Competitor Companies of VAL by Market Capitalization
Companies near ValiRx plc in the global market cap rankings as of September 18, 2026. Review VAL goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ValiRx plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
ValiRx plc Historical Marketcap From 2015 to 2026
Between 2015 and today, ValiRx plc's market cap moved from $2.84 Trillion to $ 144.62 Million, with a yearly change of -60.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | £144.62 Million | -56.72% |
| 2025 | £334.13 Million | -56.77% |
| 2024 | £772.99 Million | -86.86% |
| 2023 | £5.88 Billion | -57.86% |
| 2022 | £13.96 Billion | -61.38% |
| 2021 | £36.16 Billion | +85.90% |
| 2020 | £19.45 Billion | +30.00% |
| 2019 | £14.96 Billion | -85.45% |
| 2018 | £102.86 Billion | -81.14% |
| 2017 | £545.46 Billion | -16.67% |
| 2016 | £654.55 Billion | -76.92% |
| 2015 | £2.84 Trillion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of ValiRx plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.05 Million USD |
| MoneyControl | $3.05 Million USD |
| MarketWatch | $3.05 Million USD |
| marketcap.company | $3.05 Million USD |
| Reuters | $3.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ValiRx plc
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stag… Read more